Please assess the completion status of the following clinical trial:

Trial Title: Cytokines, PUFA Tissue Concentrations and Treatment Selection in Antenatal MDD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. women with uncomplicated pregnancies and within 24 weeks of their last menstrual period~2. describe symptoms over the previous two weeks sufficient to meet DSM IV criteria for MDD as determined by the SCID~3. have a 21-item HAM-D of 16 or more~Exclusion Criteria:~1. antidepressant use in preceding month~2. use in previous 2 wks of non-steroidal anti-inflammatory drugs (NSAIDS), antibiotics or glucocorticoids~3. use in previous 2 wks of psychotropic medications other than hypnotics or benzodiazepines in diazepam dose-equivalents greater than 2mg/day for insomnia~4. a previous diagnosis of an autoimmune disease, of hyperlipidemia, or of schizophrenia or schizoaffective disorder~5. evidence of substance dependence in previous 6 months~6. preoccupation with, or plans for, suicide~7. a history of hypersensitivity to fish or fish oil supplements~8. current use of anticoagulants~9. any current medical condition associated with clinically significant decreases in coagulability, i.e. systemic lupus erythematosis, VonWillebrend's disease~10. the initiation of regularly scheduled course of psychotherapy within the previous 2 months~11. current use of category D or category X medications

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Supplementation (Type: EXPERIMENTAL): Subjects received Omega-3 PUFA supplementation

Based on this trial design, predict the completion outcome and termination type (if applicable).